Healthy outcome under olanzapine treatment in a pregnant woman

Pharmacopsychiatry. 2000 Mar;33(2):78-80. doi: 10.1055/s-2000-7974.


Our report focuses on the case of a pregnant women with recurrent, paranoid schizophrenia. The patient was treated with Olanzapine from the 18th gestational week until delivery and during breast-feeding. No adverse events occurred during pregnancy, and the outcome was healthy. After delivery, the plasma level of olanzapine in the infant was one-third of the maternal plasma level, and during breast-feeding, it decreased to an undetectable limit.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antipsychotic Agents / adverse effects*
  • Antipsychotic Agents / therapeutic use*
  • Benzodiazepines
  • Breast Feeding
  • Female
  • Humans
  • Infant, Newborn
  • Maternal-Fetal Exchange
  • Olanzapine
  • Pirenzepine / adverse effects
  • Pirenzepine / analogs & derivatives*
  • Pirenzepine / blood
  • Pirenzepine / therapeutic use
  • Pregnancy
  • Pregnancy Outcome*
  • Schizophrenia, Paranoid / drug therapy


  • Antipsychotic Agents
  • Benzodiazepines
  • Pirenzepine
  • Olanzapine